Antispermatogenic Activity of the Benzothiazoline Ligand and Corresponding Organoantimony(V) Derivative in Male Albino Rats

Pankaj K. Sharma, 1 H. Rehwani, 2 A. K. Rai, 1 R. S. Gupta, 2 and Y. P. Singh 1

1 Department of Chemistry, University of Rajasthan, Jaipur 302 004, India
2 Reproduction Physiology Section, Department of Zoology, University of Rajasthan, Jaipur 302 004, India

Received 11 August 2005; Revised 27 November 2005; Accepted 24 January 2006

Triphenylantimony(V) derivative, Ph3Sb(OPri)[SC6H4N : C(CH3)CH2C(O)CH3], 1b, and the corresponding benzothiazoline ligand [1, 2], HNC6H4SC(CH3)CH2C(O)CH3, 1a, have been tested for their effects on the reproductive system of male albino rats. The oral administration of both 1a and 1b at the dose level of 10 mg/rat/day produced significant reduction in the weights of testes, epididymides, seminal vesicles, and ventral prostate. Significant decrease in sperm motility as well as in sperm density resulted in 100% sterility. Significant (P<.01) alterations were also found in biochemical parameters of reproductive organs in treated male rats as compared to the control group. Production of preleptotene, pachytene, and secondary spermatocytes was decreased by 42%, 43%, 39%, and by 44%, 49%, 55% in the ligand, 1a, and organoantimony(V) derivative, 1b, treated rats, respectively. These results indicate that both compounds 1a and 1b are antispermatogenic in nature and on oral administration in male rats, and finally caused sterility. A comparison indicates that the organoantimony(V) derivative 1b is more effective pertaining to its antispermatogenic activity than the corresponding ligand 1a.

INTRODUCTION

Organic compounds containing −NC6H4S− unit are well known for their significant biological activities [3]. Phenothiazines significantly affect the hypothalamic pituitary gonadal axis, resulting in a delay in ovulation and menstruation in women [3]. These effects have also been observed in rats and dogs [4, 5]. The rate of implantation was lowered, and reduction in litter size has been reported by some phenothiazine derivatives [6, 7]. In general biological activity of such type of compounds enhances considerably on complexation with metal atom [8]. We have earlier reported the antifertility activity of organoantimony(III) [9] and aluminium(III) [10] derivatives of benzothiazolines. In respect of the reproductive and developmental toxicity, antimony compounds have also been studied in experimental model. No teratogenic effects were found, when pregnant ewes and rats were treated with trivalent antimony potassium tartrate (2 mg/Kg) and antimony trichloride (0.1 and 1 mg/dl), respectively [11, 12]. Antimony had quite widespread use in pharmacology for the treatment of syphilis, fever, melancholy, pneumonia, epilepsy, and inflammatory conditions [13]. Organic antimony salts are used medically to treat some tropical diseases [14], especially in the treatment of all forms of leishmaniasis [15]. Organoantimony compounds also exhibit significant antimicrobial [16] as well as antitumor activities [17, 18], which is associated with cytostatic activity [19] similar to that for cisplatin. The biological toxicity of these derivatives is much less than that for Pt and Pd anticancer substances [19, 20]. A large number of antimony(III) compounds have also been tested as bactericides [21] and fungicides [22].

A survey of literature revealed that so far no attention has been paid to compare the effects of benzothiazoline ligand with its metal derivatives on the reproductive system of male rats. In view of this, we have synthesized and characterized the benzothiazoline ligand and its organoantimony(V) derivative. In the present publication, a comparative study among the effects on the reproductive systems of male albino rats of the corresponding ligand, 1a, and its organoantimony(V) derivative, 1b, versus control animals is presented, and also a comparison of the effects of these compounds 1a and 1b is made pertaining to their antispermatogenic activities.
EXPERIMENTAL

In view of the moisture sensitive nature of the starting materials, all the synthetic reactions were performed under moisture free conditions. All the chemicals used were of reagent grade. Solvents (E Merck) were dried by standard methods before use. Ph3SbBr2 and triphenylantimony(V) isopropoxide [24] were prepared by literature methods. The benzothiazoline ligand HNC6H4SC(CH3)CH2C(O)CH3, 1a, was prepared by the reported method [1, 2] and was purified by distillation under vacuum (85–88°C, 0.1 atm) before use. Organoantimony(V) derivative, 1b, of the benzothiazoline was prepared (Scheme 1) by the reported method [25]. Antimony was estimated iodometrically [26]. Nitrogen and sulphur were estimated by Kjeldahl’s and Messenger’s methods, respectively [26]. Isopropanol and isopropoxide were estimated by the chromate oxidimetric method [27]. Molecular weight of the organoantimony(V) derivative, 1b, was determined ebullioscopically using Beckmann’s thermometer. IR spectra of these compounds were recorded on a Nicolet DX FTIR spectrophotometer in the range 4000–200 cm\(^{-1}\) on a CsI cell. \(^1\)H and \(^13\)C NMR spectra were recorded in DMSO-\(d_6\) solution on a JEOL-FX-90Q (90 MHz) or Brucker DPX-300 MHz spectrometer, using TMS as an internal and external references, respectively.

BIOLOGICAL TESTS

Sexually mature male albino rats of laboratory bred, Wistar strain weighing about 150–175 g (90–100 days old) were used in the experiments. They were acclimatized to the normal laboratory conditions of light-dark cycle (12L:12D) with the temperature around 20 ± 5°C and 35%–60% relative humidity. Animals were given standard rat diet [Ashirwad Industries Ltd] and water ad libitum throughout the study. The animals were randomly allocated into three experimental groups of six rats each. In the first control group, only olive oil (0.5 mL/rat/day) was orally administered for 60 days. In the second and third groups, oral administration of the corresponding ligand, 1a, and its organoantimony(V) derivative, 1b, was given in olive oil at the same doses (10 mg/rat/day) for 60 days.

The fertility test of each experimental male rat was assessed by natural mating with two pro-estrous and virgin females, before, during, and after days 55 to 60 of the treatment. The presence of sperm cells in the vaginal smears was accepted as evidence of copulation. Mated females were separated and then allowed to complete the term. The number of litters delivered was recorded and used as an index for fertility of the males. Body weights of the experimental rats were monitored throughout the study. All experimental males were sacrificed under light ether anaesthesia, approximately 24 hours following the last dose. Final body weights of the animals were recorded. Blood samples were collected by cardiac puncture and serum was separated by centrifugation. Testosterone was determined by Radio Immuno Assay. Epididymal sperm motility and number of spermatozoa in the epididymides and testes were determined by the method of Prasad et al [28]. The testes, epididymides, and other accessory sex organs were excised and freed from the surrounding fat and connecting tissues and weighed. Biochemical estimations of protein, sialic acid, glycogen, cholesterol, and fructose [29–33] were carried out in testes, epididymides, and other accessory sex organs. For histopathological examination, tissues were fixed in Bouin’s fluid and several sections of the testes were prepared and stained by means of haematoxylin and eosin. Testicular cell population dynamics was determined by using “Camera Lucida” drawing. Mean seminiferous tubular diameter was determined. Various testicular cell components were quantitatively analyzed [34]. Difference between groups were compared by using one way analysis of variance (ANOVA), followed by the individual paired “T test.” Differences were considered to be statistically significant when \(P < .01\). All data are presented as mean ± SEM.

RESULTS AND DISCUSSION

Triphenylantimony(V) derivative, 1b, of the benzothiazoline ligand, 1a, has been synthesized (Scheme 1) and characterized by the reported method [25].

The light brown colored, viscous compound, 1b, is soluble in common organic solvents. Ebulloscopic molecular weight measurement reveals its monomeric nature in benzene solution as reported earlier [25].

ANTIFERTILITY ACTIVITY

Oral administration of corresponding ligand, 1a, and its antimony derivative, 1b, reduce fertility in treated rats. The body weight of the rats treated with these compounds (1a and 1b) was not affected during the course of the experiments. However, the weights of testes, epididymides, seminal
vesicles, and ventral prostate were reduced significantly ($P < .01$) in 1a and 1b treated rats than those in the control group (Table 1). Motility of spermatozoa, removed from the cauda epididymides of the treated rats (1a and 1b), was highly depressed when compared with control animals (Table 2). Sperm density in testes and in cauda epididymides was depleted significantly ($P < .01$) in both treated groups (group II and III) as compared to controls (Table 2).

Significant loss of sperm motility and density give rise to 100% sterility in 1a and 1b treated rats. Testosterone level in both the treated groups reduced significantly (Table 2). Suppressive effects of these compounds were noticed (Table 3) in protein content and sialic acid content of testes, epididymides, and other accessory sex organs. Testicular glyco- gen content and fructose content of seminal vesicles were also decreased, whereas testicular cholesterol was elevated in this investigation.

The ligand, 1a, and its corresponding metal derivative, 1b, used in this investigation resulted in weight loss of testes and other accessory sex organs mainly due to hormone deficiency. Testes produce the male gametes and a site of spermatogenesis. Spermatogenesis is regulated by pituitary hormones (FSH, LH), secreted into the peripheral circulation and by androgen, synthesized and secreted in close proximity to target sites within the testes [35]. Thus testes, epididymides, and other accessory sex organs are androgen-dependent for their growth and function. Reduction in weights may reflect a declined amount and synthesis of androgen within these organs [36]. Decrease in sperm motility and density could compromise the fertility [37]. Low sperm concentration is associated with low fertility. The spermatozoa can utilize glucose as well as fructose [38, 39]. Fructose is the main source of energy required by spermatozoa. The results from this study indicate that these compounds (1a and 1b) decrease the fructose level, since the inhibition of fructose metabolism and other physiological changes that occur at the sperm surface during the fertilization process including capacitation, acrosome reaction, and binding to the zona pellucida and oolemma [47]. Sialic acids are concerned with changing the membrane

| Treatment | Final body weight (g) | Organs weight (mg/100 gbwt) |
|-----------|-----------------------|-----------------------------|
|           | Control               |                             |
| Group-I   | 230±5.65              | 1390±20.5                   |
| P2 treated| 187.50 ± 12.5         | 1208.18* ± 56.39            |
| Group-II  | 197.50 ± 27.5         | 1286.52* ± 24.76            |
| P1 treated| 187.50 ± 27.5         | 1208.18* ± 56.39            |
|           |                      | Testes                      |
| Group-I   | 1390±20.5             | 640.25 ± 24                 |
| P2 treated| 1208.18* ± 56.39      | 466.80** ± 10.91            |
| Group-II  | 1286.52* ± 24.76      | 524.57* ± 30.83             |
| P1 treated| 1208.18* ± 56.39      | 466.80** ± 10.91            |
|           |                      | Epididymides                |
| Group-I   | 690.40 ± 16.80        | 582.84* ± 32.20             |
| P2 treated| 279.14** ± 4.44       | 582.84* ± 32.20             |
| Group-II  | 554.17** ± 4.67       | 265.85*** ± 6.85            |
| P1 treated| 265.85*** ± 6.85      | 265.85*** ± 6.85            |
|           |                      | Seminal vesicles            |
| Group-I   | 475.100 ± 12.5        | 299.14** ± 4.44             |
| P2 treated| 299.14** ± 4.44       | 299.14** ± 4.44             |
| Group-II  | 265.85*** ± 6.85      | 265.85*** ± 6.85            |
| P1 treated| 265.85*** ± 6.85      | 265.85*** ± 6.85            |
|           |                      | Ventral prostate            |
| Group-I   | 299.14** ± 4.44       | 299.14** ± 4.44             |
| P2 treated| 265.85*** ± 6.85      | 265.85*** ± 6.85            |
| Group-II  | 265.85*** ± 6.85      | 265.85*** ± 6.85            |
| P1 treated| 265.85*** ± 6.85      | 265.85*** ± 6.85            |

Table 1: Effects of compounds 1a and 1b on body and organs weight in male rats.

| Treatment | Sperm motility (%) | Sperm density (million/mL) | Fertility (%) | Testosterone ng/dL |
|-----------|--------------------|-----------------------------|--------------|-------------------|
|           | Cauda epididymides | Testes                      | Cauda epididymides |                  |
| Group-I   | 68.00 ± 1.10       | 4.10 ± 0.45                 | 100% (+ve)    | 5.25 ± 0.05       |
| Control   |                    |                             |              |                   |
| Group-II  | 27.16** ± 0.84     | 2.65* ± 0.22                | 100% (-ve)    | 2.40 ± 0.48*      |
| 1a treated|                    |                             |              |                   |
| Group-III | 21.12*** ± 0.96    | 1.90* ± 0.36                | 100% (-ve)    | 1.02 ± 0.12**     |
| 1b treated|                    |                             |              |                   |

All values are expressed as mean ± SE
Level of significance * $P < .01$; ** $P < .001$ compared to control group
a $P < .01$; b $P < .001$ compared to P1 treated group.

The results demonstrate a marked decreases in testicular glyco- gen. Such glycolytic inhibition may explain the reduced sperm motility observed in vitro in the absence of lactate and pyruvate [44, 45]. A marked decrease in the glycogen content could affect protein synthesis and thus subsequently inhibit spermatogenesis [46]. The integrity and functional activity of sperm membrane are crucial for viability and, also, for the physiological changes that occur at the sperm surface during the fertilization process including capacitation, acrosome reaction, and binding to the zona pellucida and oolemma [47]. Sialic acids are concerned with changing the membrane
Table 3: Effect of compounds 1a and 1b on biochemical parameters in male rats.

| Treatment    | Testes | Cauda epididymides | Seminal vesicle | Ventral prostate | Sialic acid (mg/g) | Testes | Cauda epididymides | Ventral prostate | Seminal vesicle | Glycogen (mg/g) | Cholesterol (mg/g) | Fructose (mg/g) |
|--------------|--------|--------------------|-----------------|-----------------|-------------------|--------|--------------------|-----------------|-----------------|----------------|-------------------|-----------------|
| Group-I      |        |                    |                 |                 |                   |        |                    |                 |                 |                |                   |                  |
| Control      | 244.05 | 224.40             | 212.45          | 208.0           | 5.18              | 6.05   | 5.45               | 5.68            |                 | 3.40            | 5.28              | 4.65            |
| Group-II     |        |                    |                 |                 |                   |        |                    |                 |                 |                |                   |                  |
| 1a treated   | 185.35** | 200.6**           | 198.60**        | 182.0**         | 4.42*             | 5.74** | 4.75**             | 5.18**          |                 | 2.48*           | 12.53*            | 3.00**          |
| 1b treated   | ±2.05  | ±0.80              | ±1.05           | ±2.02           | ±0.2              | ±0.11  | ±0.09              | ±0.02           |                 | ±0.22           | ±1.62             | ±0.11           |
| Group-III    |        |                    |                 |                 |                   |        |                    |                 |                 |                |                   |                  |
| 1a treated   | 167.00** | 190.28**           | 191.25**        | 179.5**         | 4.14**            | 5.27** | 4.47*              | 4.80**          |                 | 2.16*           | 14.18*            | 2.77**          |
| 1b treated   | ±4.42  | ±3.05              | ±1.65           | ±1.88           | ±0.10             | ±0.08  | ±0.20              | ±0.05           |                 | ±0.19           | ±2.08             | ±0.25           |

All values are expressed as mean ± SE
Level of significance * P < .01; ** P < .001 compared to control group.
* P < .01; b P < .001 compared to 1a treated group.

Table 4: Effect of compounds 1a and 1b on testicular cell population dynamics.

| Treatment    | Testicular cell counts (number/10 cross-section) | Seminiferous tubular diameter (μm) |
|--------------|-------------------------------------------------|-----------------------------------|
|              | Sertoli cell | Spermatogonia | Preleptotene spermatocyte | Pachytene spermatocyte | Secondary spermatocyte | Group-I | Control |
| Group-I      | 2.79 ± 0.05 | 6.97 ± 0.77  | 22.82 ± 1.11            | 36.42 ± 1.37          | 48.50 ± 2.85          | 250.80 ± 6.68 |
| Group-II     | 2.45* ± 0.12 | 5.89 ± 0.03  | 13.25* ± 1.30           | 20.56** ± 0.70        | 29.55* ± 1.27         | 215.25* ± 1.72 |
| Percent deviation | (−12%)   | (−15%)       | (−42%)                | (−43%)               | (−39%)               | (−14%)               |
| Group-III    | 2.32** ± 0.02 | 5.92 ± 0.72  | 14.80** ± 0.17         | 18.61** ± 1.33        | 21.93** ± 2.59        | 176.09* ± 3.03 |
| Percent deviation | (−17%)  | (−15%)       | (−44%)               | (−49%)               | (−55%)               | (−30%)               |

All values are expressed as mean ± SE
Level of significance * P < .01; ** P < .001 compared to control group.
* P < .01; b P < .001 compared to 1a treated group.
Values in parentheses are percentage reduction in particular cell type.

The surface of maturing spermatozoa and with the development of their fertilizing capacity [48]. Thus decreased sialic acid may inhibit the fertilizing capacity of sperm.

The production of preleptotene spermatocytes, pachytene spermatocytes, and secondary spermatocytes was decreased by 42%, 43%, and 39%, respectively, in 1a treated rats and by 44%, 49%, and 55%, respectively, in 1b treated rats. The total number of Sertoli cells and seminiferous tubular diameter were also reduced in 1a and 1b treated rats as compared to the control group (Table 4). Sertoli cells decreased significantly in these series of experiments. Sertoli cells synthesized and secreted ABP’s (androgen binding proteins) that are believed to serve as a reservoir for testosterone and maintaining the high intratubular concentrations, necessary for completion of spermatogenesis [49]. Alteration in the Sertoli cells affect the production of ABP which in turn lead to inhibition of the spermatogenesis [50]. The effect of metal administration produces unmistakable damage to the Sertoli cells [51]. Reduction in the number of spermatogonia, spermatocytes, and spermatids may indicate lower availability of FSH and LH, which are essential for initiation and maintenance of spermatogenesis. Cholesterol is a precursor for androgen biosynthesis and its level in testes is closely related to fertility and sperm output. Accumulation of cholesterol indicates its reduced conversion into the androgen [52]. It is known that sperm production cannot proceed optimally to completion without a continuous androgen supply [53].

From the above results it may be concluded that the benzothiazoline ligand, 1a, and its corresponding organoantimony(V) derivative, 1b, used in this investigation, are able to reduce fertility in male rats possibly by interfering the process of spermatogenesis, and it is found that the compound 1b has more suppressive effects on male reproductive systems as compared to its corresponding ligand, 1a. These results are
in close agreement with the earlier reports on the enhanced activity of metal complexes in comparison to the parent ligands [8].

ACKNOWLEDGMENTS

The award of a Junior Research Fellowship to P. K. Sharma by the University Grants Commission of India is gratefully acknowledged. We are also thankful to Dr Jagdish Prasad for statistical suggestions.

REFERENCES

[1] Sarswat BS, Srivastava G, Mehrotra RC. Schiff base complexes of organotin(IV): reactions of trimethyltin hydroxide and trialkyltin ethoxides with benzoazoline. Journal of Organometallic Chemistry. 1977;137(3):301–308.

[2] Yap G-Y, Fun H-K, Teo SB, Teoh S-G. Structure of 1-(2-methyl-2,3-dihydrobenzothiazol-2-yl)-2-propanone. Acta Crystallographica Section C. 1991;47(6):1347–1348.

[3] Gupta RR. In: Bioactive Molecules. Vol 4. Amsterdam, The Netherlands: Elsevier Press; 1988.

[4] Julou L, Dcrot R, Ganter P, et al. Toxicity of Metiazinic Acid ([10-methyl-2-phenothiazinyl) acetic acid]. Arzneim-Forsch. 1969;7(8):1207–1214.

[5] Degkwitz R, Heushgern C, Hollister LE, et al. In: Bobon DP, Jansen PAJ, Bobbon J, eds. Toxicity and Side Effect in Man and in the Laboratory Animal. Kargar Base: The Neuroleptics; 1970:671.

[6] Ravina JH. Hazardous therapeutic in the pregnant woman [in French]. Presse Medecine. 1964;72:3057–3059.

[7] Hrriington FE, Egest RG, Wlbur RD, Linkenheimer WH. Effect of coitus on chlorpromazine inhibition of ovulation in the rat. Endocrinology. 1966;79(6):1130–1134.

[8] Sorenson JR. Copper chelates as possible active forms of the antiarthritic agents. Journal of Medicinal Chemistry. 1976;19(1):135–148.

[9] Sharma RK, Dobhal MP, Singh YP, et al. Effects of organoantimony(III) compounds possessing antitumor properties: diphenylantimony(III) derivatives of dithiophosphorus ligands. Anticancer Research. 1990;10(3):803–804.

[10] Sharma S, Sharma RK, Sharma R, et al. Synthesis and characterisation of some new aluminium derivatives of schiff bases containing N, O and S donor atoms and the anti fertility activity of the derivative Al[SC6H4NH μ : C(CH3)CH2COCH3]3. Bioinorganic Chemistry & Applications. 2003;1(3-4):215–222.

[11] James L, Lazar V, Binns W. Effects of sublethal doses of certain minerals on pregnant ewes and fetal development. American Journal of Veterinary Research. 1966;27(116):132–135.

[12] Rossi F, Acampora R, Vaccà C, et al. Prenatal and postnatal antimony exposure in rats: effect on vasomotor reactivity development of pups. Teratogenesis, Carcinogenesis, and Mutagenesis. 1987;7(5):491–496.

[13] Duffin J, Campling BG. Therapy and disease concepts: the history (and future?) of antimony in cancer. Journal of the History of Medicine and Allied Sciences. 2002;57(1):61–78.

[14] Debus AG. Antimony in medical history: an account of the medical uses of antimony and its compounds since early times to the present (review). Bulletin of the History of Medicines. 2000;74(2):362–364.

[15] Demicheli C, Ochoa R, da Silva JBB, et al. Oral delivery of meglumine antimoniate-β-cyclodextrin complex for treatment of leishmaniasis. Antimicrobial Agents and Chemotherapy. 2004;48(1):100–103.

[16] Silvestru C, Haiduc I. Main Group Elements and Their Compounds. New Delhi: Narosas; 1996.

[17] Silvestru C, Silaghi-Dumitrescu L, Haiduc I, Begley MJ, Nunn M, Sowerby DB. Synthesis of diphenylantimony(III) dialkyldithtio- and dialkyldithio-phosphinates and -arsinates; crystal structures of Ph2Sb2P(M = P or As). Journal of the Chemical Society; Dalton Transactions. 1986(5):1031–1034.

[18] Silvestru C, Curtui M, Haiduc I, Begley MJ, Sowerby DB. Phenyllantimony(III) dieorganophosphorodithioates: the crystal structure of diphenylantimony(III) di-isopropylphosphorodithioate, Ph2SbP(OiPr)2. Journal of Organometallic Chemistry. 1992;426(1):49–58.

[19] Silvestru C, Socaciu C, Bara A, Haiduc I. The first organoantimony(III) compounds possessing antitumor properties: diphenylantimony(III) derivatives of dithiophosphorus ligands. Anticancer Research. 1999;10(3):803–804.

[20] Silvestru C, Haiduc I, Tiekink E, et al. Synthesis, structural characterization and in vitro antitumour properties of triorganometallic derivatives of trimethyltin: crystal and molecular structures of [3-Y-2-(ho)-C6H4COOH]2PhMe2(Y = H, Me, MeO). Applied Organometallic Chemistry. 1995;9(7):597–607.

[21] Sawant NV, Garje SS. Synthesis, characterization and biological activity of some triphenylantimony(ν) monochlororosemicarbazone complexes. Main Group Metal Chemistry. 2005;28(4):213–221.

[22] Wardell JW. In: Wilkinson G, Stone FG, Abel EW, eds. Comprehensive Organometallic Chemistry. Vol 2. Oxford, UK: Pergamon Press; 1982:681.

[23] Beveridge AD, Harris GS, Inglis F. The electrolytic conductance of halogen adducts of the triphenyl derivatives of group VB elements. Journal of the Chemical Society (A). 1966:520.

[24] McEwen WE, Briels GH, Giddings BE. Attack of alkoxide ions on antimony in tetraarylstibonium salts. Journal of the American Chemical Society. 1969;91(25):7079–7084.

[25] Sharma PK, Sharma RK, Rai AK, Singh YP. Synthesis and characterization of some triphenylantimony(ν) derivatives of N, O and S containing monofunctional bidentate ligands. Main Group Metal Chemistry. 2004;27(1):51–57.

[26] Vogel AL. In: A Text Book of Quantitative Inorganic Analysis. 5th ed. London, UK: Longman; 1989.

[27] Bradley DC, Abd-el-Halim FM, Mehrotra RC, Wardlaw W. Reactions of acetyl chloride with zirconium alkoxides. Journal of the Chemical Society. 1952:4609–4612.

[28] Prasad MRN, Chinoy NJ, Kadam KM. Changes in suc-cinic dehydrogenase levels in the rat epididymis under normal and altered physiologic conditions. Fertility and Sterility. 1972;23(3):186–190.

[29] Lowry OH, Rosenbrough NJ, Farr AL, Randall RJ. Protein measurement with the Folin phenol reagent. The Journal of Biological Chemistry. 1951;193(1):265–275.

[30] Warren L. The thiobarbituric acid assay of sialic acids. The Journal of Biological Chemistry. 1959;234(8):1971–1975.

[31] Montgomery R. Determination of glycogen. Archives of Biochemistry and Biophysics. 1957;67(2):378–386.

[32] Oser BL. In: Hawka’s Physiology Chemistry. 14th ed. New York, NY: McGraw-Hill; 1956:246.

[33] Mann T. In: Nam T, ed. Biochemistry of Semen and of the Male Reproductive Tract. London, UK: Methuen; 1964:237.

[34] Abercrombie M. Estimation of nuclear population from microtome sections. The Anatomical Record. 1946;94(2):239–247.

[35] Steinberger E, Steinberger A. In: Hamilton DW, Greep RO, eds. Handbook of Physiology, Section 7. Vol 5. Maryland, Md: Williams & Wilkins; 1973:1.
[36] Chitra KC, Latchoumycandane C, Mathur PP. Chronic effect of endosulfan on the testicular functions of rat. *Asian Journal of Andrology*. 1999;1(4):203–206.

[37] Graca A, Ramalho-Santos J, de Lourdes Pereira M. Effect of lead chloride on spermatogenesis and sperm parameters in mice. *Asian Journal of Andrology*. 2004;6(3):237–241.

[38] Eliasson R. Accurate determination of glucose in human semen. *Journal of Reproduction and Fertility*. 1965;9:325.

[39] Perez LE, Smith CG, Asch RH. Delta 9-tetrahydrocannabinol inhibits fructose utilization and motility in human, rhesus monkey, and rabbit sperm in vitro. *Fertility and Sterility*. 1981;35(6):703–705.

[40] Jadot-Van de Casseye M, Schoysman R, Smets G, Gepts W. Ultrastructural aspects of asthenospermia. *International Journal of Andrology*. 1980;3(1):15–22.

[41] Williamson RA, Koehler JK, Smith WD, Stenchever MA. Ultrastructural sperm tail defects associated with sperm immotility. *Fertility and Sterility*. 1984;41(1):103–107.

[42] Zamboni L. The ultrastructural pathology of the spermatozoon as a cause of infertility: the role of electron microscopy in the evaluation of semen quality. *Fertility and Sterility*. 1987;48(5):711–734.

[43] Dadoune JP. Ultrastructural abnormalities of human spermatozoa. *Human Reproduction*. 1988;3(3):311–318.

[44] Yeung CH, Oberlander G, Cooper TG. Effects of the male antifertility agent ornidazole on sperm function in vitro and in the female genital tract. *Journal of Reproduction and Fertility*. 1995;103(2):257–264.

[45] Cooper TG, Yeung CH, Skupin R, Haufe G. Antifertility potential of ornidazole analogues in rats. *Journal of Andrology*. 1997;18(4):431–438.

[46] Davis JR. Metabolic aspects of spermatogenesis. *Biology of Reproduction*. 1969;1(suppl 1):93–118.

[47] Liu DY, Baker HW. Tests of human sperm function and fertilization in vitro. *Fertility and Sterility*. 1992;58(3):465–483.

[48] Verma RJ, Chinoy NJ. Effect of papaya seed extract on microenvironment of cauda epididymis. *Asian Journal of Andrology*. 2001;3(2):143–146.

[49] Musto N, Gunsalvs G, Cheng CY, et al. In: Agata RD, Lipsett MB, Polosa P, Vander Molen HJ, eds. *Recent Advances in Male Reproduction: Molecular Basis and Clinical Implications*. Vol 37. New York, NY: Raven Press; 1983.

[50] Santra KB, Manna CK. Antifertility effects of methylmethanesulphonate on male reproductive organs of wild Indian house rat: histological and histochemical characteristics. *Endocrine Regulations*. 2002;36(3):123–131.

[51] Hoey MJ. The effects of metallic salts on the histology and functioning of the rat testis. *Journal of Reproduction and Fertility*. 1966;12(3):461–472.

[52] Avari KM, Bhivgade DA. Effect of depot medroxyprogesterone acetate and testosterone ananthate on the testis of albino rats: ultrastructural and biochemical studies. *Indian Journal of Experimental Biology*. 1992;30(12):1118–1127.

[53] Mohri H, Suter DA, Brown-Woodman PD, White IG, Ridley DD. Identification of the biochemical lesion produced by alpha-chlorohydrin in spermatozoa. *Nature*. 1975;255(5503):73–77.